INTRODUCTION
Allogeneic hematopoietic cell transplantation (HCT) has the potential to provide long-term survival and even cure in patients with hematological malignancies [1, 2] . Nonetheless, relapse of malignancy after HCT remains a major cause of transplantation failure. Donor lymphocyte infusion (DLI) is one approach frequently used to treat patients with relapse of hematologic malignancy after allogeneic HCT. The DLI effect is mediated through the immunologic antitumor activity of donor T cells and possibly natural killer cells [3] [4] [5] [6] . Since the first report of DLI in patients with relapsed chronic myeloid leukemia (CML) after allogeneic HCT by Kolb et al. in 1990 [6] , DLI has become a common approach to treat not only CML but also acute leukemia, lymphoma, myelodysplastic syndrome (MDS), and multiple myeloma (MM) that have relapsed after allogeneic HCT [7] [8] [9] [10] [11] [12] [13] . The beneficial graft-versus-leukemia effect of DLI may be offset by morbidity and mortality related to graft-versus-host disease (GVHD). Although a low initial cell dose followed by escalation of doses of DLI can minimize the risk of GVHD in patients treated for relapsed CML [14] [15] [16] , the data regarding the impact of initial cell dose on outcomes after DLI for other relapsed hematological malignancies are limited. The primary objective of the current study was to determine the effect of the initial DLI CD3 þ T cell dose on subsequent GVHD requiring systemic treatment and on overall survival (OS) after DLI.
PATIENTS AND METHODS
The study cohort included 225 patients treated with DLI for relapsed hematological malignancies after allogeneic HCT from November 1993 through October 2011. Patients received high-or reduced-intensity conditioning regimens before HCT according to standard treatment plan or prospective clinical trials and were treated at the Fred Hutchinson Cancer Research Center (n ¼ 212) and at 3 participant institutions in the Seattle Nonmyeloablative HCT Consortium: the University of Torino (n ¼ 9), the Puget Sound VA Health Care System (n ¼ 2), and the Medical College of Wisconsin (n ¼ 2). Follow-up was complete through July 2012. All patients provided informed consent for treatment according to transplantation protocols approved by each institutional review board. In addition, separate institutional approval was obtained to gather data from patient records and databases retrospectively.
DLI
All 225 patients in this study received DLI for treatment of relapsed hematological malignancies after HCT. No prophylactic DLI treatment was given. One hundred fifty-four patients were treated with DLI in prospective clinical trials, and 71 patients received DLI as a treatment plan. Patients with rapidly progressive malignancies (ie, acute myeloid or lymphoid leukemia, CML in blast phase, high-grade MDS, intermediate-high grade non-Hodgkin lymphoma, Hodgkin lymphoma, or aggressive multiple myeloma) received chemotherapy or radiation before DLI according to specific protocols or at the discretion of the attending physician. Treatment with tyrosine kinase inhibitor or interferon was generally discontinued before DLI. Patients were eligible to receive DLI if they were not receiving systemic treatment for GVHD, had no evidence of active GVHD at the time of DLI, and had evidence of donor chimerism. No immunosuppressive agents were given after DLI to prevent GVHD. Among 128 patients with available information regarding the DLI product, 32 patients received a granulocyte-colony stimulating factor (G-CSF) mobilized product for DLI. Twelve patients received IL-2 after DLI as part of a prospective clinical trial, as previously described [17] .
GVHD Definition DLI-related GVHD was defined as any acute GVHD [18] or chronic GVHD (NIH criteria or historical criteria) [19, 20] after DLI that required systemic treatment. As clinically acute and chronic GVHD occurring after DLI have overlapping onset times [21, 22] , for the purpose of evaluating the incidence of GVHD after DLI, we defined DLI-related GVHD as any GVHD after DLI (acute or chronic) that required systemic treatment. Serious GVHD after DLI was evaluated according to previously reported criteria [23] .
Statistical Methods
Overall survival after DLI was estimated by the Kaplan-Meier method. Cumulative incidence of relapse and GVHD after DLI were estimated by standard methods, treating death as a competing risk. Cox regression was used to evaluate risk factors for GVHD, OS, and relapse and disease progression after DLI. Risk factors evaluated in univariate analysis for each of the outcomes (GVHD, OS, and relapse or disease progression after DLI) included initial DLI CD3 þ cell dose, patient age at DLI, donor-recipient gender, diagnosis at time of DLI, disease status at time of DLI, donor origin, donor-recipient HLA match, graft stem cell source, conditioning intensity, acute and chronic GVHD before DLI, interval between HCT to DLI, cytoreductive treatment before DLI, donor blood CD3 and whole marrow chimerism at the time of DLI, lymphocyte count at the time of DLI, use of G-CSF-mobilized product for DLI, use of IL-2 after DLI, and year of DLI. Multivariate models included all factors significant at the .05 level in univariate analysis for each outcome, as well as age and the factors most significantly disparate among the cell dose groups (donor origin, conditioning intensity, and year of DLI). In analyzing the impact of subsequent DLI on overall survival, the second DLI was treated as a time-dependent covariate in a Cox regression model. Comparisons of CD3 þ cell dose between the initial and second DLI was by paired t-test.
RESULTS

Patient Characteristics
A total of 225 patients underwent treatment with DLI for persistent or relapse hematological malignancies after HCT including CML (n ¼ 56), acute myeloid leukemia (AML)
, and myeloproliferative disorder (n ¼ 1). Patients were classified into one of the following risk categories: (1) high-risk myeloid malignancies group that included patients with AML, MDS, CML (blast crisis [BC], accelerated phase [AP]), myelofibrosis, and myeloproliferative disorder, (n ¼ 111); (2) high-risk lymphoid malignancies group that included patients with ALL and high-grade lymphomas (Hodgkin lymphoma, diffuse large B cell lymphoma, transformed non-Hodgkin lymphoma), (n ¼ 37); (3) low-risk lymphoid malignancies group that included patients with CLL, MM, other lymphomas, (n ¼ 36); and (4) those with CML-chronic phase (CP) (n ¼ 41).
The median age of the 225 patient cohort was 46 years (range, 3 to 74), and 59% (n ¼ 132) were male. Patients received transplantations from HLA-matched related (n ¼ 171) or unrelated (n ¼ 41) donors. Thirteen patients had HLAmismatched donors, and 58 patients (26%) received reducedintensity conditioning regimens before HCT. The median time interval from HCT to relapse was 11.3 months (range, 1 to 180); from HCT to DLI, 15.5 months (range, 21.1 to 215). One hundred forty-four patients (64%) received cytoreductive therapy before DLI, and 55 patients (24%) had achieved complete remission at the time of DLI. The initial DLI CD3 Table 1 .
GVHD after DLI
Of the 225 treated patients, 86 (39%) developed GVHD that required systemic therapy after DLI, and 29 of 86 cases had serious GVHD as previously defined [23] . The median interval from DLI to GVHD that required systemic treatment was 39 days (range, 6 to 1029). The incidence rates of GVHD at 12 months after DLI according to initial cell dose were 21%, 45%, and 55% for groups A, B, and C, respectively ( Figure 1A) .
Results of univariate and multivariate analysis of risk factors for the development of GVHD after DLI are shown in Table 2 . In the multivariate analysis, 2 factors showed a statistically significant association with increased risk of GVHD after DLI: (1) initial DLI CD3 þ cell dose !10 Â 10 7 /kg (hazard ratio [HR], 2.4; 95% CI, 1.1 to 5.4; P ¼ .03), and (2) short interval between transplantation to DLI of 1 year or less (HR, 2.95; 95% CI, 1.7 to 5.2; P ¼ .0002) ( Table 2) . In univariate analysis, higher initial CD3 þ cell dose was associated with an increased risk for serious GVHD after DLI for group B (HR, <10 Â 10 7 CD3 þ cell/kg) and 55% (P < .0001) for initial cell dose group C (!10 Â 10 7 CD3 þ cell/kg). (B) Shows overall survival after DLI according to initial CD3 þ cell dose. Three-year overall survival rates were 47% for cell dose group A, 45% (P ¼ .16) for cell dose group B, and 32% for cell dose group C (P ¼ .01). 4.34; 95% CI, 1.4 to 13.6; P ¼ .01) and for group C (HR, 4.80; 95% CI, 1.6 to 14.7; P ¼ .006) compared to group A. Because of the small number of patients experiencing serious GVHD, multivariate analysis was not performed. Although DLI given in more recent years was associated with a decreased risk of GVHD in the univariate analysis, this factor did not reach statistical significance in the multivariate analysis. A history of acute or chronic GVHD before DLI or donor type was not statistically significantly associated with increased risk of GVHD after DLI (Table 2) .
Overall Survival after DLI
The overall survival rates at 3 years according to initial DLI cell dose were 47%, 45%, and 32% for groups A, B, and C, respectively ( Figure 1B) . At the time of analysis, 71 patients (31%) were alive after DLI. Survivors were 28 of 41 patients (68%) treated for CML-CP, 3 of 15 patients (20%) treated for CML-AP/BC, 15 of 71 patients (21%) for AML, 4 of 21 patients (19%) for ALL, 1 of 22 patients (4%) for MDS, 7 of 23 patients (30%) for MM, 2 of 8 patients (25%) for CLL, and 8 of 21 patients (38%) treated for lymphomas, 2 of 2 patients with myelofibrosis, and 1 patient with myeloproliferative disorder.
As demonstrated in Table 1 , we found no statistically significant imbalance in the distribution of diagnosis risk groups between the 3 initial DLI CD3
þ cell dose groups (P ¼ .36). Because of the small number of patients in each of the initial DLI cell dose groups in the different diagnostic risk groups (ie, CML-CP, low-risk lymphoid, low-risk myeloid, and high-risk lymphoid malignancies), these 4 diagnostic risk groups were combined into 2 risk categories for the analysis of OS according to the initial DLI CD3 þ cell dose, as follows:
(1) low-risk disease, including CML-CP, CLL, MM, low-grade lymphomas and (2) high-risk disease, including myeloid malignancies (AML, MDS, CML-AP/BC), myelofibrosis, myeloproliferative disorder, and high-risk lymphoid malignancies (ALL, high-grade lymphomas [Hodgkin lymphoma, diffuse large B cell lymphoma, transformed non-Hodgkin lymphoma]). Figure 2 shows the univariate analysis of OS after DLI according to the initial CD3 þ cell dose and the 2 diagnosis risk categories. The 3-year OS for the low-risk category was 73% for group A, 53% for group B, and 55% for group C (P ¼ .07) (Figure 2A ). The 3-year OS for the high-risk category was 27% for group A, 42% for group B, and 22% for group C, but the difference in OS between the 3 cell doses was not statistically significant (P ¼ .35) ( Figure 2B ). Univariate analysis of OS according to the initial CD3 þ cell dose for specific diagnosis such as CML and other disease categories is shown in Supplemental Figure 1 . For patients treated with DLI for relapsed CML, 3-year OS according to the initial DLI cell dose was 81% for group A, 46% for group B, and 50% for group C, but these differences did not reach statistical significance (P ¼ .07) (Supplemental Figure 1A) . For patients given DLI for relapsed lymphoma, CLL, and MM, the 1-and 3-year OS were 85% and 43%, respectively, for patients given cell dose A; 91% and 64%, respectively for patients treated with cell dose B; and 46% and 31%, respectively, for cell dose C. These differences were not statistically significant (P ¼ .25) (Supplemental Figure 1B) . No association between initial DLI CD3 þ cell dose and OS was noted for patients treated for relapsed AML or MDS with 3-year OS of 32%, 40%, and 28% for initial DLI CD3 þ cell doses A, B and C, respectively (P ¼ .99) (Supplemental Figure 1C) . Results of multivariate analysis for risk factors for mortality after DLI are presented in Table 3 . Three factors were statistically significantly associated with an increased risk of mortality after DLI: (1) DLI within 1 year after HCT (HR, 2.66; 95% CI, 1.7 to 4.2; P < .0001); (2) age 60 or older (HR, 2.69; 95% CI, 1.1 to 6.3; P ¼ .02); and (3) high-risk lymphoid malignancies (HR, 2.62; 95% CI, 1.0 to 6.8; P ¼ .05). As shown in Table 2 , a trend for an association between high-risk myeloid malignancies and an increased mortality risk was noted (P ¼ .06). More recent DLI was associated with decreased risk for mortality, with an HR of .27 (95% CI, .1 to .6; P ¼ .002) for patients treated with DLI between 2007 to 2011 compared with patients treated between 1992 to 1996. Initial DLI cell dose did not affect mortality either for the entire cohort (Table 3 ) or for the cohort of patients with diseases other than CML-CP (group B: HR, .88; P ¼ .61; group C: HR, 1.22; P ¼ .51).
Of the 225 patients, 46 received 2 DLIs, 13 patients received 3 DLIs, and 1 patient received 4 DLIs. A timedependent Cox regression analysis showed no significant effect of subsequent DLIs on OS (HR, .95; 95% CI, .6 to 1.4, P ¼ .82). for the low-risk category. One-and 3-year overall survival were 94% and 73% for cell dose A, 67% and 53% for cell dose B, and 60% and 55% for cell dose C (P ¼ .07). Low-risk category included chronic myeloid leukemia-chronic phase and chronic lymphocytic leukemia, multiple myeloma, and low-risk lymphomas. (B) Shows the overall survival for the high-risk category. Oneand 3-year overall survival were 47% and 27% for cell dose group A, 60% and 42% for cell dose group B, and 41% and 22% for cell dose group C (P ¼ .35). High-risk category included high-risk myeloid malignancies (acute myeloid leukemia, myelodysplastic syndrome, chronic myeloid leukemia [blast crisis, accelerated phase], myelofibrosis, myeloproliferative disorders, and high-risk lymphoid malignancies [acute lymphoblastic leukemia, high-grade lymphomas [Hodgkin lymphoma, diffuse large B cell lymphoma, transformed non-Hodgkin lymphoma]). 
Causes of Death
A total of 154 patients have died. Deaths occurred in 49 of 84 patients (58%) in cell group A, in 41 of 58 patients (71%) in cell dose group B, and in 55 of 66 patients (83%) in cell group C. The most common cause of death after DLI was progressive disease or relapse of malignancy in all 3 cell dose groups: 90% of deaths in group A, 73% of deaths in group B, and 67% of deaths in group C. GVHD was the primary cause of death in 4 patients (8%) in group A, 3 patients (7%) in group B, and 5 patients (9%) in group C. 
DISCUSSION
DLI is an attractive salvage treatment option for patients with persistent or relapsed hematological malignancies after high-or reduced-intensity HCT [7] [8] [9] [10] [11] . Previous studies have suggested optimal initial total nucleated cells and lymphocyte doses of DLI associated with a low risk of GVHD and mortality and yet maintenance of the desirable graft-versusmalignancy effect for treatment of relapsed CML after allogeneic HCT [14] [15] [16] . Limited data are available on the impact of DLI CD3 þ cell dose on GVHD and mortality after DLI in patients treated for other hematological malignancies, however, and the appropriate initial cell dose of DLI for treatment of recurrent non-CML hematological malignancies after HCT remained unsettled. Thus, the primary objective of our study was to determine the effect of the initial DLI cell dose on GVHD and OS after DLI in patients treated for any hematological malignancies that relapsed after allogeneic HCT. DLI contains a variety of cell types, and the response to DLI could be mediated by several mechanisms. T lymphocytes have significant effects on both graft-versus-leukemia and GVHD because of their longevity after transfusion in vivo and their ability to target minor histocompatibility antigens shared between leukemic and normal host tissue as well as antigens unique to leukemia cells [24] [25] [26] . Therefore, we focused our analysis on the effect of the initial CD3 þ T cell dose on GVHD and survival after DLI. This retrospective analysis of 225 patients confirms that adoptive immunotherapy with donor lymphocytes may be an effective treatment for patients with hematological malignancies who experience relapse after allogeneic HCT, and the results suggest that the initial CD3 þ cell dose may influence the outcome independently of other relevant factors.
Our multivariate analysis suggests that the risk for developing GVHD after DLI significantly increases with CD3 þ cell dose !10 Â 10 7 /kg, regardless of diagnosis, pre-DLI acute or chronic GVHD, or interval between HCT and DLI. GVHD, a pathological process initiated by the activation of donor T cell after adoptive transfer into the allogeneic recipient [27] , has been a major direct complication after DLI [7, 17, 24, [28] [29] [30] [31] [32] [33] [34] . Earlier reports demonstrated that the dose of allogeneic total nucleated cells and lymphocytes infused for DLI is a risk factor of GVHD after DLI in patients with relapsed CML [14, 21, 30] . Chalendon et al. showed that >1 Â 10 7 CD3 þ cells/ kg was correlated with a higher frequency of GVHD after DLI in patients with relapsed CML after HCT [21] . In our study, initial DLI CD3 þ cell dose of !10 Â 10 7 /kg was associated with a 2.4-fold increase in the risk of GVHD after DLI compared with cell doses 1.0 Â 10 7 in patients treated for any hematological malignancy that relapsed or progressed after allogeneic HCT after either high-intensity or reducedintensity conditioning. Initial DLI CD3 þ cell dose of >1.0 Â 10 7 to <10 Â 10 7 /kg was not associated with an increased risk for GVHD compared to a lower cell dose.
We then sought to determine the effect of the initial CD3 þ cell dose on OS after DLI. Earlier studies evaluated the effect of DLI mononuclear cells or T cell dose for the treatment of CML [14, 15] . Guglielmi et al. demonstrated that for the treatment of relapsed CML, an initial DLI cell dose of .20 Â 10 8 mononuclear cells/kg was associated with less GVHD and better survival than higher mononuclear cell doses [14] . Similar to the findings by Guglielmi et al., we demonstrated better OS for patients with relapsed CML who were treated with lower initial DLI CD3 þ cell dose. Although our association did not reach statistical significance, likely because of the small cohort, our and earlier results demonstrate that for patients with CML, initial CD3 þ cell dose of 1 Â 10 7 or lower has survival advantage as compared to higher CD3 þ cell dose.
In contrast to the association between initial DLI CD3 þ cell dose and OS in CML, we did not demonstrate such an association for patients with AML or MDS. Earlier analyses to evaluate the correlation between cell dose and response rate in AML showed that increasing the cell dose beyond 1.5 Â 10 8 T cell/kg did not add to the response rate [35] . A study by Choi et al., however, appeared to show a better response rate with a higher dose of T cells [36] . In our study, we demonstrated 3-year overall survival of 32%, 40%, and 28% for 
